Discovery and bioactivity of 4-(2-arylpyrido[3′,2′:3,4]pyrrolo[1,2-f][1,2,4]-triazin-4-yl) morpholine derivatives as novel PI3K inhibitors

被引:17
作者
Wang, Jia [1 ]
Wang, Xiang [1 ]
Chen, Yanhong [1 ]
Chen, Simeng [1 ]
Chen, Guang [1 ]
Tong, Linjiang [1 ]
Meng, Linghua [1 ]
Xie, Yuyuan [1 ]
Ding, Jian [1 ]
Yang, Chunhao [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, SIBS, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金;
关键词
PI3K; Cancer; PI-103; analogs; 3-KINASES; CANCER; POTENT; PTEN;
D O I
10.1016/j.bmcl.2011.11.003
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
PI3K is a promising therapeutic target for cancer. With PI-103 as the lead compound, we designed and synthesized 4-(2-arylpyrido[3',2':3,4] pyrrolo[1,2-f][1,2,4]triazin-4-yl)morpholine derivatives. 9, 10a, 10d, 10e had the IC50 against PI3K alpha comparable with PI-103. All of the compounds showed selectivity over 15 tested protein kinases and anti-proliferative activity at micromolar concentration against several cancer cell lines. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:339 / 342
页数:4
相关论文
共 12 条
[1]  
[Anonymous], J MED CHEM
[2]   Oncogenic PI3K deregulates transcription and translation [J].
Bader, AG ;
Kang, SY ;
Zhao, L ;
Vogt, PK .
NATURE REVIEWS CANCER, 2005, 5 (12) :921-929
[3]  
Bradley S.E., 2005, U.S. Patent, Patent No. [2005261272A1, 2005261272]
[4]   Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors [J].
Kong, Dexin ;
Yamori, Takao .
CURRENT MEDICINAL CHEMISTRY, 2009, 16 (22) :2839-2854
[5]   Targeting the phosphoinositide 3-kinase pathway in cancer [J].
Liu, Pixu ;
Cheng, Hailing ;
Roberts, Thomas M. ;
Zhao, Jean J. .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (08) :627-644
[6]   Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799 [J].
Ohwada, Jun ;
Ebiike, Hirosato ;
Kawada, Hatsuo ;
Tsukazaki, Masao ;
Nakamura, Mitsuaki ;
Miyazaki, Takuya ;
Morikami, Kenji ;
Yoshinari, Kiyoshi ;
Yoshida, Miyuki ;
Kondoh, Osamu ;
Kuramoto, Shino ;
Ogawa, Kotaro ;
Aoki, Yuko ;
Shimma, Nobuo .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (06) :1767-1772
[7]   Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases [J].
Raynaud, Florence I. ;
Eccles, Suzanne ;
Clarke, Paul A. ;
Hayes, Angela ;
Nutley, Bernard ;
Alix, Sonia ;
Henley, Alan ;
Di-Stefano, Francesca ;
Ahmad, Zahida ;
Guillard, Sandrine ;
Bjerke, Lynn M. ;
Kelland, Lloyd ;
Valenti, Melanie ;
Patterson, Lisa ;
Gowan, Sharon ;
Brandon, Alexis de Haven ;
Hayakawa, Masahiko ;
Kaizawa, Hiroyuki ;
Koizumi, Tomonubu ;
Ohishi, Takahide ;
Patel, Sonal ;
Saghir, Nahid ;
Parker, Peter ;
Waterfield, Mike ;
Workman, Paul .
CANCER RESEARCH, 2007, 67 (12) :5840-5850
[8]   High frequency of mutations of the PIK3CA gene in human cancers [J].
Samuels, Y ;
Wang, ZH ;
Bardelli, A ;
Silliman, N ;
Ptak, J ;
Szabo, S ;
Yan, H ;
Gazdar, A ;
Powell, DM ;
Riggins, GJ ;
Willson, JKV ;
Markowitz, S ;
Kinzler, KW ;
Vogelstein, B ;
Velculescu, VE .
SCIENCE, 2004, 304 (5670) :554-554
[9]   Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN [J].
Stambolic, V ;
Suzuki, A ;
de la Pompa, JL ;
Brothers, GM ;
Mirtsos, C ;
Sasaki, T ;
Ruland, J ;
Penninger, JM ;
Siderovski, DP ;
Mak, TW .
CELL, 1998, 95 (01) :29-39
[10]   Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer [J].
Sutherlin, Daniel P. ;
Sampath, Deepak ;
Berry, Megan ;
Castanedo, Georgette ;
Chang, Zhigang ;
Chuckowree, Irina ;
Dotson, Jenna ;
Folkes, Adrian ;
Friedman, Lori ;
Goldsmith, Richard ;
Heffron, Tim ;
Lee, Leslie ;
Lesnick, John ;
Lewis, Cristina ;
Mathieu, Simon ;
Nonomiya, Jim ;
Olivero, Alan ;
Pang, Jodie ;
Prior, Wei Wei ;
Salphati, Laurent ;
Sideris, Steve ;
Tian, Qingping ;
Tsui, Vickie ;
Wan, Nan Chi ;
Wang, Shumei ;
Wiesmann, Christian ;
Wong, Susan ;
Zhu, Bing-Yan .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (03) :1086-1097